ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 25.3% during trading on Tuesday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). Approximately 65,638,188 shares changed hands during mid-day trading, an increase of 677% from the average daily volume of 8,446,959 shares. The stock had previously closed at GBX 13.98 ($0.19).
ImmuPharma Stock Down 12.2%
The company has a market cap of £77.24 million, a PE ratio of -1,736.74 and a beta of 1.53. The company has a 50-day moving average of GBX 3.43 and a 200-day moving average of GBX 3.01.
ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
(
Get Free Report)
ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.
While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
